Product Description
HE3286, a synthetic derivative of androst-5-ene-3_,7_,17_-triol (AET), a non-glucocorticoid anti-inflammatory metabolite of the adrenal steroid, dehydroepiandrosterone is under development by Harbor BioSciences as an anti-inflammatory; antiepileptic drugs; antihyperglycemic agent. (Sourced from: https://drugs.ncats.io/drug/PH8858757I)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Harbor
Company Location: Western America
Company CEO: Christine R. Deister
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colitis, Ulcerative|Arthritis, Rheumatoid|Type 2 Diabetes
Phase 1: Insulin Resistance
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00991107 |
HE3286-0103 | P1 |
Completed |
Insulin Resistance |
2010-08-01 |
2019-03-19 |
Treatments |
|
NCT00555451 |
HE3286-0102 | P1 |
Completed |
Insulin Resistance |
2009-09-01 |
2019-03-22 |
Treatments |
|
NCT00694057 |
HE3286-0401 | P2 |
Completed |
Type 2 Diabetes |
2010-01-01 |
2019-03-18 |
||
NCT00712114 |
HE3286-0201 | P2 |
Completed |
Arthritis, Rheumatoid |
2009-07-01 |
2019-03-18 |
Treatments |
|
NCT00628433 |
HE3286-0301 | P2 |
Completed |
Colitis, Ulcerative |
2009-05-01 |
2019-03-18 |
Treatments |